2026-08-19

Moderna Stock Nearly Triples to $174 as mRNA Melanoma Vaccine Beats Keytruda Alone in Phase 3 - Merck Jumps 6.5% Too

Written & reviewed by the TradeSmrt editorial team · 2026-08-19

In this article

What Happened
Why a Trial Result Alone Can Double a Stock Overnight
What to Take Away From This
FAQ
Sources

What Happened

Moderna (NASDAQ: MRNA) shares nearly tripled in Wednesday trading, surging over 100% intraday before closing up 176.97% at $174.38 - up from a prior close of roughly $62.96. It was, by a wide margin, the best single trading day in the company's history as a public company. The catalyst was a joint announcement with Merck (NYSE: MRK): their personalized mRNA cancer vaccine, known in trials as intismeran (formerly mRNA-4157/V940), met the main goal of a Phase 3 study in high-risk melanoma patients when combined with Merck's blockbuster immunotherapy Keytruda. Merck's own stock, while a much smaller company-wide move given its size, still rose roughly 6.5% on the news - a significant single-day pop for a pharmaceutical giant of Merck's scale.

The trial, run in patients who had surgically removed high-risk melanoma, compared the intismeran-plus-Keytruda combination against Keytruda alone, which has been the standard of care in this setting for years. The combination significantly extended the time patients lived without their melanoma returning or spreading - the study's primary endpoint - and separately reduced the risk of the cancer metastasizing to distant parts of the body, a secondary but clinically critical measure. Neither company has yet released the full numerical breakdown (the specific percentage risk reduction or median outcomes), but both said they plan to present detailed results at an upcoming medical conference and to discuss the data with regulators for a potential filing.

What makes this result unusually significant isn't just the size of the stock move - it's what the trial represents scientifically. This is the first mRNA-based cancer therapy of any kind to succeed in a late-stage (Phase 3), randomized clinical trial. Moderna and Merck have been developing intismeran together since a 2022 collaboration deal, built on Moderna's mRNA delivery platform - the same core technology behind its COVID-19 vaccine, but repurposed here in a very different way. Rather than teaching the immune system to recognize a virus, intismeran is manufactured individually for each patient: doctors sequence the mutations unique to that patient's own tumor, then use those mutations to design a personalized mRNA vaccine intended to train the patient's immune system to recognize and attack cancer cells carrying that specific genetic signature.

Why a Trial Result Alone Can Double a Stock Overnight

To understand why the market reaction was this extreme, it helps to understand what Moderna's stock price had been pricing in beforehand. Since COVID-19 vaccine demand collapsed from its 2021 peak, Moderna's core commercial business has shrunk dramatically, and the company has been burning cash while its pipeline of next-generation products - flu vaccines, RSV vaccines, and various cancer and rare-disease therapies - worked through years of expensive, uncertain clinical trials with no guarantee any single one would succeed. In that environment, Moderna's stock had been trading at levels that reflected a market largely skeptical that its post-COVID pipeline would produce a genuine commercial winner. A single successful Phase 3 readout for what many analysts consider the most promising asset in that pipeline forces a rapid repricing, because it converts a speculative, binary "might work" scenario into a "this works, now it's a matter of regulatory approval and commercial execution" scenario almost overnight.

This is a structural pattern worth understanding, not a one-off quirk of Moderna. Clinical-stage and early-commercial biotech and pharma stocks are frequently priced around a small number of binary catalysts - a trial readout, an FDA decision date, a conference data presentation - because so much of the company's future value depends on whether that one program succeeds or fails. When the answer flips from unknown to "yes, it worked," the stock doesn't drift upward the way a typical earnings beat might move a mature company's shares; it can re-rate all at once, because the market is repricing a probability, not adjusting a growth estimate. The mirror image is just as real: a failed Phase 3 trial can cut a similarly speculative biotech stock in half or worse in a single session. That asymmetry - modest, gradual gains most of the time, and occasional violent moves on binary readouts - is simply the nature of investing in clinical-stage biotech, and it cuts both ways.

Merck's smaller, but still meaningful, 6.5% gain illustrates the same dynamic at a different scale. Keytruda is already Merck's largest product by revenue, generating tens of billions of dollars annually, but it faces looming patent expiration later this decade - a fact Wall Street has been anxiously pricing in for years. A next-generation combination therapy that extends Keytruda's clinical relevance and commercial life, potentially opening an entirely new revenue stream in adjuvant melanoma treatment (and, if the platform generalizes, other solid tumors down the line), directly addresses one of the biggest overhangs on Merck's long-term growth story. That's why even a company of Merck's size can see a real, single-digit-percentage stock move on a partner's trial data.

It's also worth being precise about what today's announcement did and did not confirm. This was topline data - the headline result that the trial met its primary endpoint - not the full dataset, and not a regulatory approval. Full efficacy numbers, safety data, and duration of benefit will only become clear once both companies present complete results at a medical conference and file with regulators such as the FDA. Historically, some drugs that post strong topline Phase 3 results still face regulatory delays, labeling restrictions, or reimbursement hurdles that affect how quickly - and how profitably - they actually reach patients. None of that changes the significance of today's scientific milestone, but it is the reason experienced biotech investors typically treat a topline readout as the start of a new phase of uncertainty (regulatory and commercial) rather than the end of the story.

What to Take Away From This

Binary catalysts create binary stock moves. When a company's valuation depends heavily on the outcome of one clinical trial, FDA decision, or similar single event, the stock can move by dramatic percentages in a single session - in either direction. If you hold, or are considering holding, a clinical-stage biotech stock, understand what event is coming and treat it as a real coin-flip risk, not background noise.
A stock beaten down by a fading legacy business can still hold hidden option value in its pipeline. Moderna's core COVID vaccine revenue had been declining for years, but the stock's eventual reaction shows the market hadn't fully priced out the possibility that a pipeline bet could pay off. Don't assume a company's most recent, most visible business line tells the whole story of what the stock is worth.
Topline trial data is the beginning of the next uncertainty, not the end of it. A successful Phase 3 readout still needs to clear full data presentation, regulatory review, and commercial launch before it translates into actual revenue. Chasing a stock purely on a headline "trial succeeded" move, without understanding what still has to happen afterward, is a common mistake.
Watch how a catalyst ripples to partners and peers, not just the headline company. Merck's 6.5% gain on a partner's data, and the broader lift to biotech sentiment that followed, shows that a single trial result can move an entire group of related stocks - both the direct beneficiary and companies perceived to be in a similar position.

FAQ

Why did Moderna's stock react so much more strongly than Merck's to the same news?

Because the two companies are very different sizes relative to this one drug. For Merck, intismeran is one promising program within a massive, diversified pharmaceutical business with many other products generating revenue - so even great news moves the stock only a few percentage points. For Moderna, a much smaller company whose post-COVID pipeline had been the subject of significant market skepticism, this single successful trial represents a much larger share of its total expected future value, so the same news produces a far larger percentage move.

Does this mean intismeran is now an approved cancer treatment?

No. Wednesday's announcement was topline Phase 3 data showing the trial met its main goal - not an FDA approval. Moderna and Merck still need to present full detailed results at a medical conference, submit the complete dataset to regulators, and go through the standard approval review process before the treatment could become available to patients broadly.

Is it safe to buy Moderna stock now after this jump?

That depends entirely on an individual investor's own research and risk tolerance, and this article isn't investment advice. What's worth understanding is that the stock has already re-rated sharply on this news, meaning much of the good news is already reflected in the current price, and the next catalysts (full data presentation, regulatory review, competitive response) carry their own separate uncertainty.

Sources

This article is an original synthesis and analysis based on the reporting below, not a reproduction of the original articles. Please check the source articles directly for the most current figures and details.

⚠️ This article is for informational purposes only and is not investment advice. Market conditions change constantly - always verify the latest data before making investment decisions.